ERBB2 and neoplasm: Additionally, the study revealed that the combination of the anti-human epidermal growth factor 2 (HER2) circRNA-CAR (referred to as circRNA-Anti-HER2-CAR) and a circRNA vaccine encoding HER2 antigen elicited a strong anti-tumor immune response [99].